By: Andrew A Radin CEO & Co-founder, Aria Pharmaceuticals 2021 was a year of growth and transformational change at Aria Pharmaceuticals. In recognition of our continued evolution, we announced a rebrand to a new name that reflects the artistry and complexity that defines how our company and scientific teams approach…

By: Anjali Pandey, Ph.D. SVP of Nonclincal R&D & Chemistry at Aria Pharmaceuticals Idiopathic pulmonary fibrosis (IPF) is devastating. It causes lung tissue scarring that becomes thicker over time, causing chronic pain and difficulty breathing. However, it’s not just the physical toll of the disease that impacts patients, it’s also…

By: Andrew A. Radin CEO& Co-founder, Aria Pharmaceuticals Since we have now rebranded twoXAR Pharmaceuticals as Aria Pharmaceuticals, I’m often asked “Why that name?” The dictionary defines the word “aria” as a long musical piece typically written for a solo voice with orchestral accompaniment in an opera, a theatrical work…

by: Mark Eller, Ph.D. SVP of R&D, Aria Pharmaceuticals I recently authored an article in Life Science Leader discussing my own misperceptions and preconceived notions about applying AI to an extremely challenging and complex process, drug discovery. Like many, my 30-year career in pharmaceuticals was rooted in the tried-and-true methodology…

Andrew A. Radin CEO, twoXAR Pharmaceuticals Every year, for the past 39 years, the J.P. Morgan Healthcare Conference has been one of the most reliable predictors of our industry’s health. It’s a gauge of industry innovation, deal making, funding and overall sentiment about the value of the pharmaceutical market. However…

Andrew A. Radin CEO, twoXAR Pharmaceuticals Without a doubt, 2020 has been a trying year. The pandemic has touched every business and every human on earth in different ways. …

by: Andrew A. Radin CEO, twoXAR I recently authored an article for MedCity News discussing the hype surrounding AI, especially as it relates to fighting COVID-19. Since the very beginning of this pandemic, researchers and pharmaceutical companies have been working around the clock to find treatments and, more importantly, develop…

by: Aaron Daugherty This week we are celebrating the release of the 250th version of our drug discovery software platform! …

by: Andrew A. Radin CEO, twoXAR I met Tim for the first time almost three years ago and I remember our meeting well. He furrowed his brow slightly as I explained the details on how our technology creates computational models of pathogenesis to derive new understanding of disease, and then…